Filed with the SEC on · accession 0001140361-26-044354
PCRX filed a 8-K (current report) with the SEC on Nov 17, 2026. Viatris Inc. completed its acquisition of Pacira BioSciences via a tender offer at $36.50 per share in cash, making Pacira a wholly owned subsidiary.
Viatris Inc. completed its acquisition of Pacira BioSciences via a tender offer at $36.50 per share in cash, making Pacira a wholly owned subsidiary. In connection with the merger, Pacira settled its 2.125% Convertible Senior Notes due 2029 into cash and terminated its credit agreement.
✦ Ask GOAX AI about this filing — what it means for PCRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PCRX?
Click herePCRX filed a 8-K (Acquisition). Viatris Inc. completed its acquisition of Pacira BioSciences via a tender offer at $36.50 per share in cash, making Pacira a wholly owned subsidiary. In connection with the merger, Pacira settled its 2.125% Convertible Senior Notes due 2029 into cash and terminated its credit agreement.
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when PCRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days